Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sotelo Monge, Katiaca
- dc.contributor.author Gálvez-Ruiz, Albertoca
- dc.contributor.author Alvárez-Carrón, Albertoca
- dc.contributor.author Quijada, Césarca
- dc.contributor.author Matheu, Annaca
- dc.date.accessioned 2015-11-06T09:54:28Z
- dc.date.available 2015-11-06T09:54:28Z
- dc.date.issued 2015
- dc.description.abstract The drug dasatinib is a new therapeutic option for patients with chronic myeloid leukemia (CML) as well as acute lymphocytic lymphoblastic leukemia (ALL). However, the scientific literature has not reached a consensus regarding the types of secondary ophthalmologic effects that this drug may have. In this study, we present the case of a 36-year-old male patient who was treated with dasatinib. Two and a half months later, this patient began to experience progressive visual loss in the superior visual field of both eyes. After ruling out various diagnostic options and performing extensive complementary tests, the suspected diagnosis was compatible with optic neuropathy secondary to dasatinib. The patient partially improved after stopping this medication and receiving oral corticosteroid treatment. Although secondary ophthalmological effects related to dasatinib are practically non-existent, our case is the first to report optic neuropathy secondary to this drug.ca
- dc.format.mimetype application/pdfca
- dc.identifier.citation Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, Quijada C, Matheu A. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015 Jul-Sep;29(3):227-31. doi: 10.1016/j.sjopt.2014.12.004.ca
- dc.identifier.doi http://dx.doi.org/10.1016/j.sjopt.2014.12.004
- dc.identifier.issn 1319-4534
- dc.identifier.uri http://hdl.handle.net/10230/25014
- dc.language.iso engca
- dc.publisher Elsevierca
- dc.relation.ispartof Saudi Journal of Ophthalmology. 2015 Jul-Sep;29(3):227-31
- dc.rights 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.sjopt.2014.12.004ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ca
- dc.subject.other Leucèmia mieloide agudaca
- dc.subject.other Oftalmologiaca
- dc.title Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.ca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca